Loading stock data…
$2.36-0.04 (-1.67%)
Exicure, Inc.
Exicure, Inc. in the Healthcare sector is trading at $2.36 with a market capitalization of $17M. The stock is currently near its 52-week low of $1.71, remaining 43.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.60M↑ | -$2.26M↑ | -$2.39M↑ | -$2.45M↑ | -$3.02M |
| Net Income | -$1.83M↑ | -$2.90M↓ | -$2.44M↑ | -$2.62M↓ | $3.01M |
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combi...